Referências
Principais artigos
Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. Resumo
Internation Parkinson and Movement Disorder Society. MDS position paper: diagnosis of Parkinson's disease. Mar 2023 [internet publication].Texto completo
Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-57.Texto completo Resumo
Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease - an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98.Texto completo Resumo
Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66.Texto completo Resumo
Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary. Neurosurgery. 2018 Jun 1;82(6):753-6.Texto completo Resumo
Artigos de referência
1. Postuma RB, Berg D, Stern M, et al. MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2015 Oct;30(12):1591-601. Resumo
2. Quinn N, Crtichley P, Marsden CD. Young onset Parkinson's disease. Mov Disord. 1987;2:73-91. Resumo
3. Bower JH, Maraganore DM, McDonnell SK, et al. Incidence and distribution of parkinsonism in Olmsted County, Minnesota, 1976-1990. Neurology. 1999 Apr 12;52(6):1214-20. Resumo
4. Riccò M, Vezzosi L, Balzarini F, et al. Prevalence of Parkinson disease in Italy: a systematic review and meta-analysis. Acta Biomed. 2020 Sep 7;91(3):e2020088.Texto completo Resumo
5. GBD 2016 Parkinson's Disease Collaborators. Global, regional, and national burden of Parkinson's disease, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet Neurol. 2018 Nov;17(11):939-53.Texto completo Resumo
6. Pringsheim T, Jette N, Frolkis A, et al. The prevalence of Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2014 Nov;29(13):1583-90. Resumo
7. Okubadejo NU, Bower JH, Rocca WA, et al. Parkinson's disease in Africa: a systematic review of epidemiologic and genetic studies. Mov Disord. 2006 Dec;21(12):2150-6. Resumo
8. Ma CL, Su L, Xie JJ, et al. The prevalence and incidence of Parkinson's disease in China: a systematic review and meta-analysis. J Neural Transm (Vienna). 2014 Feb;121(2):123-34. Resumo
9. Van Den Eeden SK, Tanner CM, Bernstein AL, et al. Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity. Am J Epidemiol. 2003 Jun 1;157(11):1015-22.Texto completo Resumo
10. Wright Willis A, Evanoff BA, Lian M, et al. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34(3):143-51.Texto completo Resumo
11. Dahodwala N, Karlawish J, Siderowf A, et al. Delayed Parkinson's disease diagnosis among African-Americans: the role of reporting of disability. Neuroepidemiology. 2011;36(3):150-4.Texto completo Resumo
12. Marras C, Beck JC, Bower JH, et al. Prevalence of Parkinson's disease across North America. NPJ Parkinsons Dis. 2018 Jul 10;4:21.Texto completo Resumo
13. Hirsch L, Jette N, Frolkis A, et al. The incidence of Parkinson's disease: a systematic review and meta-analysis. Neuroepidemiology. 2016;46(4):292-300.Texto completo Resumo
14. Georgiev D, Hamberg K, Hariz M, et al. Gender differences in Parkinson's disease: a clinical perspective. Acta Neurol Scand. 2017 Dec;136(6):570-84. Resumo
15. Armstrong MJ, Okun MS. Diagnosis and treatment of Parkinson disease: a review. JAMA. 2020 Feb 11;323(6):548-60. Resumo
16. Nalls MA, Blauwendraat C, Vallerga CL, et al. Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurol. 2019 Dec;18(12):1091-102. Resumo
17. Bloem BR, Okun MS, Klein C. Parkinson's disease. Lancet. 2021 Jun 12;397(10291):2284-303. Resumo
18. Blauwendraat C, Nalls MA, Singleton AB. The genetic architecture of Parkinson's disease. Lancet Neurol. 2020 Feb;19(2):170-8. Resumo
19. Fang J, Hou B, Liu H, et al. Association between SNCA rs2736990 polymorphism and Parkinson's disease: a meta-analysis. Neurosci Lett. 2017 Sep 29;658:102-7. Resumo
20. Liu X, Zhu R, Xiao T, et al. An updated analysis with 45,078 subjects confirms the association between SNCA rs11931074 and Parkinson's disease. Neurol Sci. 2018 Dec;39(12):2061-9. Resumo
21. Zhao H, Kong Z. Relationship between LRRK2 R1628P polymorphism and Parkinson's disease in Asian populations. Oncotarget. 2016 Jul 26;7(30):46890-8.Texto completo Resumo
22. Funayama M, Nishioka K, Li Y, et al. Molecular genetics of Parkinson's disease: contributions and global trends. J Hum Genet. 2022 Jul 11 [Epub ahead of print].Texto completo Resumo
23. Sidransky E, Nalls MA, Aasly JO, et al. Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease. N Engl J Med. 2009 Oct 22;361(17):1651-61.Texto completo Resumo
24. Neumann J, Bras J, Deas E, et al. Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease. Brain. 009 Jul;132(Pt 7):1783-94.Texto completo Resumo
25. Blauwendraat C, Reed X, Krohn L, et al. Genetic modifiers of risk and age at onset in GBA associated Parkinson's disease and Lewy body dementia. Brain. 2020 Jan 1;143(1):234-48.Texto completo Resumo
26. He T, Wang J, Wang X, et al. Association between PARK16 and Parkinson's disease: a meta-analysis. Neurosci Lett. 2017 Aug 12;657:179-88. Resumo
27. Liu L, Zhang L, Guo L, et al. MTHFR C677T and A1298C polymorphisms may contribute to the risk of Parkinson's disease: a meta-analysis of 19 studies. Neurosci Lett. 2017 Oct 31;662:339-45. Resumo
28. Fagan ES, Pihlstrøm L. Genetic risk factors for cognitive decline in Parkinson's disease: a review of the literature. Eur J Neurol. 2017 Apr;24(4):561-e20. Resumo
29. Sayad M, Zouambia M, Chaouch M, et al. Greater improvement in LRRK2 G2019S patients undergoing subthalamic nucleus deep brain stimulation compared to non-mutation carriers. BMC Neurosci. 2016 Feb 1;17:6.Texto completo Resumo
30. Langston JW. The MPTP story. J Parkinsons Dis. 2017;7(s1):S11-9.Texto completo Resumo
31. Bjorklund G, Stejskal V, Urbina MA, et al. Metals and Parkinson's disease: mechanisms and biochemical processes. Curr Med Chem. 2018;25(19):2198-214. Resumo
32. Oueslati A, Ximerakis M, Vekrellis K. Protein transmission, seeding and degradation: key steps for alpha-synuclein prion-like propagation. Exp Neurobiol. 2014 Dec;23(4):324-36.Texto completo Resumo
33. Wichmann T, DeLong MR. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv Neurol. 2003;91:9-18. Resumo
34. Jankovic J, Ben-Arie L, Schwartz K, et al. Movement and reaction times and fine coordination tasks following pallidotomy. Mov Disord. 1999 Jan;14(1):57-62. Resumo
35. Vingerhoets FJ, Schulzer M, Calne DB, et al. Which clinical sign of Parkinson's disease best reflects the nigrostriatal lesion? Ann Neurol. 1997 Jan;41(1):58-64. Resumo
36. Dostrovsky JO, Hutchinson WD, Lozano AM. The globus pallidus, deep brain stimulation and Parkinson's disease. Neuroscientist. 2002 Jun;8(3):284-90. Resumo
37. Tatton WG, Lee RG. Evidence for abnormal long-loop reflexes in rigid Parkinsonian patients. Brain Res. 1975 Dec 26;100(3):671-6. Resumo
38. Horak FB, Nutt JG, Nashner LM. Postural inflexibility in parkinsonism subjects. J Neurol Sci. 1992 Aug;111(1):46-58. Resumo
39. Hedreen JC. Tyrosine hydroxylase-immunoreactive elements in the human globus pallidus and subthalamic nucleus. J Comp Neurol. 1999 Jul 5;409(3):400-10. Resumo
40. Koller W, Pahwa R, Busenbark K, et al. High-frequency unilateral thalamic stimulation in the treatment of essential and parkinsonian tremor. Ann Neurol. 1997 Sep;42(3):292-9. Resumo
41. Lee RG, Stein RB. Resetting of tremor by mechanical perturbations: a comparison of essential tremor and parkinsonian tremor. Ann Neurol. 1981 Dec;10(6):523-31. Resumo
42. Braak H, Del Tredici K, Rub U, et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol Aging. 2003 Mar-Apr;24(2):197-211. Resumo
43. Braak H, de Vos RA, Bohl J, et al. Gastric alpha-synuclein immunoreactive inclusions in Meissner's and Auerbach's plexuses in cases staged for Parkinson's disease-related brain pathology. Neurosci Lett. 2006 Mar 20;396(1):67-72. Resumo
44. Bloch A, Probst A, Bissig H, et al. Alpha-synuclein pathology of the spinal and peripheral autonomic nervous system in neurologically unimpaired elderly subjects. Neuropathol Appl Neurobiol. 2006 Jun;32(3):284-95. Resumo
45. Kasten M, Hartmann C, Hampf J, et al. Genotype-phenotype relations for the Parkinson's disease genes Parkin, PINK1, DJ1: MDSGene systematic review. Mov Disord. 2018 May;33(5):730-41. Resumo
46. Langston JW, Ballard P, Tetrud JW, et al. Chronic Parkinsonism in humans due to a product of meperidine-analog synthesis. Science. 1983 Feb 25;219(4587):979-80. Resumo
47. Mortimer JA, Borenstein AR, Nelson LM. Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis. Neurology. 2012 Sep 11;79(11):1174-80.Texto completo Resumo
48. Du K, Liu MY, Pan YZ, et al. Association of circulating manganese levels with Parkinson's disease: a meta-analysis. Neurosci Lett. 2018 Feb 5;665:92-8. Resumo
49. Botsford E, George J, Buckley EE. Parkinson's disease and metal storage disorders: a systematic review. Brain Sci. 2018 Oct 31;8(11):194.Texto completo Resumo
50. Marder K, Tang MX, Mejia H, et al. Risk of Parkinson's disease among first-degree relatives: a community-based study. Neurology. 1996 Jul;47(1):155-60. Resumo
51. Nicoletti A, Vasta R, Mostile G, et al. Head trauma and Parkinson's disease: results from an Italian case-control study. Neurol Sci. 2017 Oct;38(10):1835-9. Resumo
52. Jafari S, Etminan M, Aminzadeh F, et al. Head injury and risk of Parkinson disease: a systematic review and meta-analysis. Mov Disord. 2013 Aug;28(9):1222-9. Resumo
53. Kenborg L, Rugbjerg K, Lee PC, et al. Head injury and risk for Parkinson disease: results from a Danish case-control study. Neurology. 2015 Mar 17;84(11):1098-103.Texto completo Resumo
54. Martino R, Candundo H, Lieshout PV, et al. Onset and progression factors in Parkinson's disease: a systematic review. Neurotoxicology. 2017 Jul;61:132-41. Resumo
55. Priyadarshi A, Khuder SA, Schaub EA, et al. Environmental risk factors and Parkinson's disease: a metaanalysis. Environ Res. 2001 Jun;86(2):122-7. Resumo
56. Schoenberg BS. Environmental risk factors for Parkinson's disease: the epidemiologic evidence. Can J Neurol Sci. 1987 Aug;14(3 suppl):407-13. Resumo
57. Pezzoli G, Cereda E. Exposure to pesticides or solvents and risk of Parkinson disease. Neurology. 2013 May 28;80(22):2035-41. Resumo
58. Yan D, Zhang Y, Liu L, et al. Pesticide exposure and risk of Parkinson's disease: dose-response meta-analysis of observational studies. Regul Toxicol Pharmacol. 2018 Jul;96:57-63. Resumo
59. Tangamornsuksan W, Lohitnavy O, Sruamsiri R, et al. Paraquat exposure and Parkinson's disease: a systematic review and meta-analysis. Arch Environ Occup Health. 2019;74(5):225-38. Resumo
60. Barbosa ER, Leiros da Costa MD, Bacheschi LA, et al. Parkinsonism after glycine-derivate exposure. Mov Disord. 2001 May;16(3):565-8. Resumo
61. National Academies of Sciences, Engineering, and Medicine; Health and Medicine Division; Board on Population Health and Public Health Practice; Committee to Review the Health Effects in Vietnam Veterans of Exposure to Herbicides (Eleventh Biennial Update). Veterans and Agent Orange: update 11 (2018). Washington, DC: The National Academies Press; 2018.Texto completo Resumo
62. Schulte PA, Burnett CA, Boeniger MF, et al. Neurodegenerative diseases: occupational occurrence and potential risk factors, 1982 through 1991. Am J Public Health. 1996 Sep;86(9):1281-8.Texto completo Resumo
63. Frigerio R, Elbaz A, Sanft KR, et al. Education and occupations preceding Parkinson disease: a population-based case-control study. Neurology. 2005 Nov 22;65(10):1575-83. Resumo
64. Valdés EG, Andel R, Sieurin J, et al. Occupational complexity and risk of Parkinson's disease. PLoS One. 2014;9(9):e106676.Texto completo Resumo
65. Sieurin J, Andel R, Tillander A, et al. Occupational stress and risk for Parkinson's disease: a nationwide cohort study. Mov Disord. 2018 Sep;33(9):1456-64.Texto completo Resumo
66. Pouchieu C, Piel C, Carles C, et al. Pesticide use in agriculture and Parkinson's disease in the AGRICAN cohort study. Int J Epidemiol. 2018 Feb 1;47(1):299-310.Texto completo Resumo
67. Internation Parkinson and Movement Disorder Society. MDS position paper: diagnosis of Parkinson's disease. Mar 2023 [internet publication].Texto completo
68. Pfeiffer RF. Non-motor symptoms in Parkinson's disease. Parkinsonism Relat Disord. 2016 Jan;22 Suppl 1:S119-22. Resumo
69. Postuma RB, Poewe W, Litvan I, et al. Validation of the MDS clinical diagnostic criteria for Parkinson's disease. Mov Disord. 2018 Oct;33(10):1601-8. Resumo
70. Schapira AHV, Chaudhuri KR, Jenner P. Non-motor features of Parkinson disease. Nat Rev Neurosci. 2017 Jul;18(7):435-50. Resumo
71. Knudsen K, Krogh K, Østergaard K, et al. Constipation in Parkinson's disease: subjective symptoms, objective markers, and new perspectives. Mov Disord. 2017 Jan;32(1):94-105. Resumo
72. Schrag A, Barone P, Brown RG, et al. Depression rating scales in Parkinson's disease: critique and recommendations. Mov Disord. 2007 Jun 15;22(8):1077-92.Texto completo Resumo
73. Lawton M, Hu MT, Baig F, et al. Equating scores of the University of Pennsylvania Smell Identification Test and Sniffin' Sticks test in patients with Parkinson's disease. Parkinsonism Relat Disord. 2016 Dec;33:96-101.Texto completo Resumo
74. Nielsen T, Jensen MB, Stenager E, et al. The use of olfactory testing when diagnosing Parkinson's disease - a systematic review. Dan Med J. 2018 May;65(5):A5481. Resumo
75. Ponsen MM, Stoffers D, Booij J, et al. Idiopathic hyposmia as a preclinical sign of Parkinson's disease. Ann Neurol. 2004 Aug;56(2):173-81. Resumo
76. Kägi G, Bhatia KP, Tolosa E. The role of DAT-SPECT in movement disorders. J Neurol Neurosurg Psychiatry. 2010 Jan;81(1):5-12. Resumo
77. Kalra S, Grosset DG, Benamer HT. Differentiating vascular parkinsonism from idiopathic Parkinson's disease: a systematic review. Mov Disord. 2010 Jan 30;25(2):149-56. Resumo
78. Koros C, Simitsi AM, Prentakis A, et al. DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. Parkinsonism Relat Disord. 2020 Aug;77:36-42. Resumo
79. American College of Radiology. ACR–ACNM–SNMMI practice parameter for the performance of dopamine transporter (DaT) single photon emission computed tomography (SPECT) imaging for movement disorders. 2022 [internet publication].Texto completo
80. Orimo S, Suzuki M, Inaba A, et al. 123I-MIBG myocardial scintigraphy for differentiating Parkinson's disease from other neurodegenerative parkinsonism: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2012 Jun;18(5):494-500. Resumo
81. Braune S. The role of cardiac metaiodobenzylguanidine uptake in the differential diagnosis of parkinsonian syndromes. Clin Auton Res. 2001 Dec;11(6):351-5. Resumo
82. Treglia G, Stefanelli A, Cason E, et al. Diagnostic performance of iodine-123-metaiodobenzylguanidine scintigraphy in differential diagnosis between Parkinson's disease and multiple-system atrophy: a systematic review and a meta-analysis. Clin Neurol Neurosurg. 2011 Dec;113(10):823-9. Resumo
83. Berardelli A, Wenning GK, Antonini A, et al. EFNS/MDS-ES/ENS recommendations for the diagnosis of Parkinson's disease. Eur J Neurol. 2013 Jan;20(1):16-34.Texto completo Resumo
84. Chang D, Nalls MA, Hallgrímsdóttir IB, et al. A meta-analysis of genome-wide association studies identifies 17 new Parkinson's disease risk loci. Nat Genet. 2017 Oct;49(10):1511-6.Texto completo Resumo
85. Kuzkina A, Schulmeyer L, Monoranu CM, et al. The aggregation state of α-synuclein deposits in dermal nerve fibers of patients with Parkinson's disease resembles that in the brain. Parkinsonism Relat Disord. 2019 Jul;64:66-72. Resumo
86. Donadio V. Skin nerve α-synuclein deposits in Parkinson's disease and other synucleinopathies: a review. Clin Auton Res. 2019 Dec;29(6):577-85. Resumo
87. Gelb DJ, Oliver E, Gilman S. Diagnostic criteria for Parkinson disease. Arch Neurol. 1999 Jan;56(1):33-9. Resumo
88. Bhatia KP, Bain P, Bajaj N, et al; Tremor Task Force of the International Parkinson and Movement Disorder Society. Consensus statement on the classification of tremors. From the Task Force on Tremor of the International Parkinson and Movement Disorder Society. Mov Disord. 2018 Jan;33(1):75-87.Texto completo Resumo
89. Deuschl G, Bain P, Brin M. Consensus statement of the Movement Disorder Society on Tremor. Ad Hoc Scientific Committee. Mov Disord. 1998;13 Suppl 3:2-23. Resumo
90. Reiter E, Mueller C, Pinter B, et al. Dorsolateral nigral hyperintensity on 3.0T susceptibility-weighted imaging in neurodegenerative parkinsonism. Mov Disord. 2015 Jul;30(8):1068-76. Resumo
91. Cho SJ, Bae YJ, Kim JM, et al. Iron-sensitive magnetic resonance imaging in Parkinson's disease: a systematic review and meta-analysis. J Neurol. 2021 Dec;268(12):4721-36. Resumo
92. Höglinger GU, Respondek G, Stamelou M, et al; Movement Disorder Society-endorsed PSP Study Group. Clinical diagnosis of progressive supranuclear palsy: the Movement Disorder Society criteria. Mov Disord. 2017 Jun;32(6):853-64.Texto completo Resumo
93. Wenning GK, Ben-Shlomo Y, Hughes A, et al. What clinical features are most useful to distinguish definite multiple system atrophy from Parkinson's disease? J Neurol Neurosurg Psychiatry. 2000 Apr;68(4):434-40.Texto completo Resumo
94. Zupancic M, Mahajan A, Handa K. Dementia with Lewy bodies: diagnosis and management for primary care providers. Prim Care Companion CNS Disord. 2011;13(5):PCC.11r01190.Texto completo Resumo
95. McKeith IG, Boeve BF, Dickson DW, et al. Diagnosis and management of dementia with Lewy bodies: Fourth consensus report of the DLB Consortium. Neurology. 2017 Jul 4;89(1):88-100.Texto completo Resumo
96. Goetz CG, Tilley BC, Shaftman SR, et al; Movement Disorder Society UPDRS Revision Task Force. Movement Disorder Society-sponsored revision of the Unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. Mov Disord. 2008 Nov 15;23(15):2129-70.Texto completo Resumo
97. Hughes AJ, Daniel SE, Kilford L, et al. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J Neurol Neurosurg Psychiatry. 1992 Mar;55(3):181-4.Texto completo Resumo
98. García-Ramos R, Santos-García D, Alonso-Cánovas A, et al. Management of Parkinson's disease and other movement disorders in women of childbearing age: part 1 [in Spanish]. Neurologia (Engl Ed). 2021 Mar;36(2):149-58. Resumo
99. Pringsheim T, Day GS, Smith DB, et al; Guideline Subcommittee of the AAN. Dopaminergic therapy for motor symptoms in early Parkinson disease practice guideline summary: a report of the AAN Guideline Subcommittee. Neurology. 2021 Nov 16;97(20):942-57.Texto completo Resumo
100. National Institute for Health and Care Excellence. Parkinson's disease in adults. Jul 2017 [internet publication].Texto completo
101. Luis-Martínez R, Monje MHG, Antonini A, et al. Technology-enabled care: integrating multidisciplinary care in Parkinson's disease through digital technology. Front Neurol. 2020 Oct 30;11:575975.Texto completo Resumo
102. Lima LO, Scianni A, Rodrigues-de-Paula F. Progressive resistance exercise improves strength and physical performance in people with mild to moderate Parkinson's disease: a systematic review. J Physiother. 2013 Mar;59(1):7-13. Resumo
103. Tomlinson CL, Patel S, Meek C, et al. Physiotherapy versus placebo or no intervention in Parkinson's disease. Cochrane Database Syst Rev. 2013 Sep 10;(9):CD002817.Texto completo Resumo
104. Schindler A, Pizzorni N, Cereda E, et al. Consensus on the treatment of dysphagia in Parkinson's disease. J Neurol Sci. 2021 Nov 15;430:120008.Texto completo Resumo
105. Welsby E, Berrigan S, Laver K. Effectiveness of occupational therapy intervention for people with Parkinson's disease: systematic review. Aust Occup Ther J. 2019 Dec;66(6):731-8. Resumo
106. Allen NE, Sherrington C, Paul SS, et al. Balance and falls in Parkinson's disease: a meta-analysis of the effect of exercise and motor training. Mov Disord. 2011 Aug 1;26(9):1605-15. Resumo
107. Rao AK. Enabling functional independence in Parkinson's disease: update on occupational therapy intervention. Mov Disord. 2010;25(suppl 1):S146-51. Resumo
108. Corcos DM, Robichaud JA, David FJ, et al. A two-year randomized controlled trial of progressive resistance exercise for Parkinson's disease. Mov Disord. 2013 Aug;28(9):1230-40.Texto completo Resumo
109. Osborne JA, Botkin R, Colon-Semenza C, et al. Physical therapist management of Parkinson disease: a clinical practice guideline from the American Physical Therapy Association. Phys Ther. 2022 Apr 1;102(4):pzab302.Texto completo Resumo
110. Radder DLM, Lígia Silva de Lima A, Domingos J, et al. Physiotherapy in Parkinson's disease: a meta-analysis of present treatment modalities. Neurorehabil Neural Repair. 2020 Oct;34(10):871-80.Texto completo Resumo
111. Fidan O, Seyyar GK, Aras B, et al. The effect of Tai Chi and Qigong on health-related quality of life in Parkinson's disease: a systematic review and meta-analysis of systematic reviews. Int J Rehabil Res. 2019 Sep;42(3):196-204. Resumo
112. Bega D, Gonzalez-Latapi P, Zadikoff C, et al. A review of the clinical evidence for complementary and alternative therapies in Parkinson's disease. Curr Treat Options Neurol. 2014 Oct;16(10):314. Resumo
113. Zhou Z, Zhou R, Wei W, et al. Effects of music-based movement therapy on motor function, balance, gait, mental health, and quality of life for patients with Parkinson's disease: a systematic review and meta-analysis. Clin Rehabil. 2021 Jul;35(7):937-51. Resumo
114. Dos Santos Delabary M, Komeroski IG, Monteiro EP, et al. Effects of dance practice on functional mobility, motor symptoms and quality of life in people with Parkinson's disease: a systematic review with meta-analysis. Aging Clin Exp Res. 2018 Jul;30(7):727-35. Resumo
115. García-Casares N, Martín-Colom JE, García-Arnés JA. Music therapy in Parkinson's disease. J Am Med Dir Assoc. 2018 Dec;19(12):1054-62. Resumo
116. Cugusi L, Manca A, Bergamin M, et al. Aquatic exercise improves motor impairments in people with Parkinson's disease, with similar or greater benefits than land-based exercise: a systematic review. J Physiother. 2019 Apr;65(2):65-74.Texto completo Resumo
117. Gomes Neto M, Pontes SS, Almeida LO, et al. Effects of water-based exercise on functioning and quality of life in people with Parkinson's disease: a systematic review and meta-analysis. Clin Rehabil. 2020 Dec;34(12):1425-35. Resumo
118. Ni M, Hazzard JB, Signorile JF, et al. Exercise guidelines for gait function in Parkinson's disease: a systematic review and meta-analysis. Neurorehabil Neural Repair. 2018 Oct;32(10):872-86.Texto completo Resumo
119. McDonnell MN, Rischbieth B, Schammer TT, et al. Lee Silverman Voice Treatment (LSVT)-BIG to improve motor function in people with Parkinson's disease: a systematic review and meta-analysis. Clin Rehabil. 2018 May;32(5):607-18. Resumo
120. Peterka M, Odorfer T, Schwab M, et al. LSVT-BIG therapy in Parkinson's disease: physiological evidence for proprioceptive recalibration. BMC Neurol. 2020 Jul 11;20(1):276.Texto completo Resumo
121. Rutz DG, Benninger DH. Physical therapy for freezing of gait and gait impairments in Parkinson disease: a systematic review. PM R. 2020 Nov;12(11):1140-56. Resumo
122. Kashif M, Ahmad A, Bandpei MAM, et al. Combined effects of virtual reality techniques and motor imagery on balance, motor function and activities of daily living in patients with Parkinson's disease: a randomized controlled trial. BMC Geriatr. 2022 Apr 30;22(1):381.Texto completo Resumo
123. Lu Y, Ge Y, Chen W, et al. The effectiveness of virtual reality for rehabilitation of Parkinson disease: an overview of systematic reviews with meta-analyses. Syst Rev. 2022 Mar 19;11(1):50.Texto completo Resumo
124. Lina C, Guoen C, Huidan W, et al. The effect of virtual reality on the ability to perform activities of daily living, balance during gait, and motor function in Parkinson disease patients: a systematic review and meta-analysis. Am J Phys Med Rehabil. 2020 Oct;99(10):917-24. Resumo
125. Seppi K, Ray Chaudhuri K, Coelho M, et al. Update on treatments for nonmotor symptoms of Parkinson's disease - an evidence-based medicine review. Mov Disord. 2019 Feb;34(2):180-98.Texto completo Resumo
126. Baillon S, Dennis M, Lo N, et al. Screening for depression in Parkinson's disease: the performance of two screening questions. Age Ageing. 2014 Mar;43(2):200-5.Texto completo Resumo
127. Broen MP, Narayen NE, Kuijf ML, et al. Prevalence of anxiety in Parkinson's disease: a systematic review and meta-analysis. Mov Disord. 2016 Aug;31(8):1125-33. Resumo
128. Hong CT, Tan S, Huang TW. Psychotherapy for the treatment of anxiety and depression in patients with Parkinson disease: a meta-analysis of randomized controlled trials. J Am Med Dir Assoc. 2021 Nov;22(11):2289-95.e2. Resumo
129. Zečević I. Clinical practice guidelines based on evidence for cognitive-behavioural therapy in Parkinson's disease comorbidities: a literature review. Clin Psychol Psychother. 2020 Jul;27(4):504-14. Resumo
130. Lawrence BJ, Gasson N, Bucks RS, et al. Cognitive training and noninvasive brain stimulation for cognition in Parkinson's disease: a meta-analysis. Neurorehabil Neural Repair. 2017 Jul;31(7):597-608. Resumo
131. Alzahrani H, Venneri A. Cognitive rehabilitation in Parkinson's disease: a systematic review. J Parkinsons Dis. 2018;8(2):233-45. Resumo
132. da Silva FC, Iop RDR, de Oliveira LC, et al. Effects of physical exercise programs on cognitive function in Parkinson's disease patients: a systematic review of randomized controlled trials of the last 10 years. PLoS One. 2018 Feb 27;13(2):e0193113.Texto completo Resumo
133. Negida A, Menshawy A, El Ashal G, et al. Coenzyme Q10 for patients with Parkinson's disease: a systematic review and meta-analysis. CNS Neurol Disord Drug Targets. 2016;15(1):45-53. Resumo
134. Zhou Z, Zhou R, Zhang Z, et al. The association between vitamin D status, vitamin D supplementation, sunlight exposure, and Parkinson's disease: a systematic review and meta-analysis. Med Sci Monit. 2019 Jan 23;25:666-74.Texto completo Resumo
135. Luthra NS, Kim S, Zhang Y, et al. Characterization of vitamin D supplementation and clinical outcomes in a large cohort of early Parkinson's disease. J Clin Mov Disord. 2018 Oct 31;5:7.Texto completo Resumo
136. Chang MC, Kwak SG, Kwak S. Effect of dietary vitamins C and E on the risk of Parkinson's disease: a meta-analysis. Clin Nutr. 2021 Jun;40(6):3922-30. Resumo
137. Fox SH, Katzenschlager R, Lim SY, et al. International Parkinson and Movement Disorder Society evidence-based medicine review: update on treatments for the motor symptoms of Parkinson's disease. Mov Disord. 2018 Aug;33(8):1248-66.Texto completo Resumo
138. Thanvi B, Treadwell S. Drug induced parkinsonism: a common cause of parkinsonism in older people. Postgrad Med J. 2009 Jun;85(1004):322-6. Resumo
139. Chen F, Jin L, Nie Z. Safety and efficacy of rotigotine for treating Parkinson's disease: a meta-analysis of randomised controlled trials. J Pharm Pharm Sci. 2017;20(0):285-94. Resumo
140. Zhu J, Chen M. The effect and safety of ropinirole in the treatment of Parkinson disease: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Nov 19;100(46):e27653.Texto completo Resumo
141. Binde CD, Tvete IF, Gåsemyr JI, et al. Comparative effectiveness of dopamine agonists and monoamine oxidase type-B inhibitors for Parkinson's disease: a multiple treatment comparison meta-analysis. Eur J Clin Pharmacol. 2020 Dec;76(12):1731-43.Texto completo Resumo
142. Stocchi F, Antonini A, Berg D, et al. Safinamide in the treatment pathway of Parkinson's disease: a European Delphi Consensus. NPJ Parkinsons Dis. 2022 Feb 21;8(1):17.Texto completo Resumo
143. Rascol O, Hauser RA, Stocchi F, et al. Long-term effects of rasagiline and the natural history of treated Parkinson's disease. Mov Disord. 2016 Oct;31(10):1489-96. Resumo
144. Stowe R, Ives N, Clarke CE, et al. Evaluation of the efficacy and safety of adjuvant treatment to levodopa therapy in Parkinson's disease patients with motor complications. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD007166.Texto completo Resumo
145. Li J, Lou Z, Liu X, et al. Efficacy and safety of adjuvant treatment with entacapone in advanced Parkinson's disease with motor fluctuation: a systematic meta-analysis. Eur Neurol. 2017;78(3-4):143-53.Texto completo Resumo
146. Katsaiti I, Nixon J. Are there benefits in adding catechol-o methyltransferase inhibitors in the pharmacotherapy of Parkinson's disease patients? A systematic review. J Parkinsons Dis. 2018;8(2):217-31. Resumo
147. Ferreira JJ, Lees A, Rocha JF, et al. Opicapone as an adjunct to levodopa in patients with Parkinson's disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol. 2016 Feb;15(2):154-65. Resumo
148. Lees AJ, Ferreira J, Rascol O, et al. Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol. 2017 Feb 1;74(2):197-206.Texto completo Resumo
149. Wang Y, Jiang DQ, Lu CS, et al. Efficacy and safety of combination therapy with pramipexole and levodopa vs levodopa monotherapy in patients with Parkinson disease: a systematic review and meta-analysis. Medicine (Baltimore). 2021 Nov 5;100(44):e27511.Texto completo Resumo
150. Giossi R, Carrara F, Mazzari M, et al. Overall efficacy and safety of safinamide in Parkinson's disease: a systematic review and a meta-analysis. Clin Drug Investig. 2021 Apr;41(4):321-39.Texto completo Resumo
151. Jiang DQ, Wang HK, Wang Y, et al. Rasagiline combined with levodopa therapy versus levodopa monotherapy for patients with Parkinson's disease: a systematic review. Neurol Sci. 2020 Jan;41(1):101-9. Resumo
152. Jiang DQ, Li MX, Jiang LL, et al. Comparison of selegiline and levodopa combination therapy versus levodopa monotherapy in the treatment of Parkinson's disease: a meta-analysis. Aging Clin Exp Res. 2020 May;32(5):769-79. Resumo
153. Hauser RA, Hsu A, Kell S, et al. Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial. Lancet Neurol. 2013 Apr;12(4):346-56. Resumo
154. LeWitt PA, Huff FJ, Hauser RA, et al. Double-blind study of the actively transported levodopa prodrug XP21279 in Parkinson's disease. Mov Disord. 2014 Jan;29(1):75-82. Resumo
155. Stocchi F, Hsu A, Khanna S, et al. Comparison of IPX066 with carbidopa-levodopa plus entacapone in advanced PD patients. Parkinsonism Relat Disord. 2014 Dec;20(12):1335-40.Texto completo Resumo
156. Paton DM. Istradefylline: adenosine A2A receptor antagonist to reduce "OFF" time in Parkinson's disease. Drugs Today (Barc). 2020 Feb;56(2):125-34. Resumo
157. Isaacson SH, Betté S, Pahwa R. Istradefylline for OFF episodes in Parkinson's disease: a US perspective of common clinical scenarios. Degener Neurol Neuromuscul Dis. 2022 Jul 23;12:97-109.Texto completo Resumo
158. Sako W, Murakami N, Motohama K, et al. The effect of istradefylline for Parkinson's disease: a meta-analysis. Sci Rep. 2017 Dec 21;7(1):18018.Texto completo Resumo
159. Takahashi M, Fujita M, Asai N, et al. Safety and effectiveness of istradefylline in patients with Parkinson's disease: interim analysis of a post-marketing surveillance study in Japan. Expert Opin Pharmacother. 2018 Oct;19(15):1635-42.Texto completo Resumo
160. Lang AE, Houeto JL, Krack P, et al. Deep brain stimulation: preoperative issues. Mov Disord. 2006 Jun;21 (suppl 14):S171-96. Resumo
161. Peng L, Fu J, Ming Y, et al. The long-term efficacy of STN vs GPi deep brain stimulation for Parkinson disease: a meta-analysis. Medicine (Baltimore). 2018 Aug;97(35):e12153.Texto completo Resumo
162. Antonini A, Odin P, Pahwa R, et al. The long-term impact of levodopa/carbidopa intestinal gel on 'off'-time in patients with advanced Parkinson's disease: a systematic review. Adv Ther. 2021 Jun;38(6):2854-90.Texto completo Resumo
163. Deuschl G, Antonini A, Costa J, et al. European Academy of Neurology/Movement Disorder Society - European Section guideline on the treatment of Parkinson's disease: I. Invasive therapies. Eur J Neurol. 2022 Sep;29(9):2580-95.Texto completo Resumo
164. Katzenschlager R, Poewe W, Rascol O, et al. Apomorphine subcutaneous infusion in patients with Parkinson's disease with persistent motor fluctuations (TOLEDO): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet Neurol. 2018 Sep;17(9):749-59. Resumo
165. Olanow CW, Factor SA, Espay AJ, et al; CTH-300 Study investigators. Apomorphine sublingual film for off episodes in Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 study. Lancet Neurol. 2020 Feb;19(2):135-44. Resumo
166. Hui JS, Fox SH, Neeson W, et al; CTH-300 Study Investigators. Open-label titration of apomorphine sublingual film in patients with Parkinson's disease and "OFF" episodes. Parkinsonism Relat Disord. 2020 Oct;79:110-6.Texto completo Resumo
167. LeWitt PA, Hauser RA, Pahwa R, et al. Safety and efficacy of CVT-301 (levodopa inhalation powder) on motor function during off periods in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2019 Feb;18(2):145-54. Resumo
168. Rughani A, Schwalb JM, Sidiropoulos C, et al. Congress of Neurological Surgeons systematic review and evidence-based guideline on subthalamic nucleus and globus pallidus internus deep brain stimulation for the treatment of patients with Parkinson's disease: executive summary. Neurosurgery. 2018 Jun 1;82(6):753-6.Texto completo Resumo
169. Suarez-Cedeno G, Suescun J, Schiess MC. Earlier intervention with deep brain stimulation for Parkinson's disease. Parkinsons Dis. 2017;2017:9358153.Texto completo Resumo
170. Mansouri A, Taslimi S, Badhiwala JH, et al. Deep brain stimulation for Parkinson's disease: meta-analysis of results of randomized trials at varying lengths of follow-up. J Neurosurg. 2018 Apr;128(4):1199-213.Texto completo Resumo
171. Wong JK, Cauraugh JH, Ho KWD, et al. STN vs. GPi deep brain stimulation for tremor suppression in Parkinson disease: a systematic review and meta-analysis. Parkinsonism Relat Disord. 2019 Jan;58:56-62.Texto completo Resumo
172. Zhang J, Li J, Chen F, et al. STN versus GPi deep brain stimulation for dyskinesia improvement in advanced Parkinson's disease: a meta-analysis of randomized controlled trials. Clin Neurol Neurosurg. 2021 Feb;201:106450. Resumo
173. Taylor LP, Besbris JM, Graf WD, et al. Clinical guidance in neuropalliative care: an AAN position statement. Neurology. 2022 Mar 8;98(10):409-16.Texto completo Resumo
174. European Medicines Agency. CMDh confirms recommendations on restricting use of domperidone-containing medicines. Apr 2014 [internet publication].Texto completo
175. Mulvaney CA, Duarte GS, Handley J, et al. GLP-1 receptor agonists for Parkinson's disease. Cochrane Database Syst Rev. 2020 Jul 23;(7):CD012990.Texto completo Resumo
176. Xie YJ, Gao Q, He CQ, et al. Effect of repetitive transcranial magnetic stimulation on gait and freezing of gait in Parkinson disease: a systematic review and meta-analysis. Arch Phys Med Rehabil. 2020 Jan;101(1):130-40. Resumo
177. Nascimento LR, do Carmo WA, de Oliveira GP, et al. Transcranial direct current stimulation provides no clinically important benefits over walking training for improving walking in Parkinson's disease: a systematic review. J Physiother. 2021 Jul;67(3):190-6.Texto completo Resumo
178. Chen J, He P, Zhang Y, et al. Non-pharmacological treatment for Parkinson disease patients with depression: a meta-analysis of repetitive transcranial magnetic stimulation and cognitive-behavioral treatment. Int J Neurosci. 2021 Apr;131(4):411-24. Resumo
179. Nardone R, Versace V, Brigo F, et al. Transcranial magnetic stimulation and gait disturbances in Parkinson's disease: a systematic review. Neurophysiol Clin. 2020 Jul;50(3):213-25. Resumo
180. Lench DH, DeVries W, Kearney-Ramos TE, et al. Paired inhibitory stimulation and gait training modulates supplemental motor area connectivity in freezing of gait. Parkinsonism Relat Disord. 2021 Jul;88:28-33.Texto completo Resumo
181. Moore SF, Guzman NV, Mason SL, et al. Which patients with Parkinson's disease participate in clinical trials? One centre's experiences with a new cell based therapy trial (TRANSEURO). J Parkinsons Dis. 2014;4(4):671-6. Resumo
182. ClinicalTrials.gov. TRANSEURO open label transplant study in Parkinson's disease (TRANSEURO). NCT01898390. Apr 2019 [internet publication].Texto completo
183. ClinicalTrials.gov. A study to evaluate the safety of neural stem cells in patients with Parkinson's disease. NCT02452723. Apr 2019 [internet publication].Texto completo
184. Barker RA; TRANSEURO consortium. Designing stem-cell-based dopamine cell replacement trials for Parkinson's disease. Nat Med. 2019 Jul;25(7):1045-53. Resumo
185. Richardson RM, Bankiewicz KS, Christine CW, et al. Data-driven evolution of neurosurgical gene therapy delivery in Parkinson's disease. J Neurol Neurosurg Psychiatry. 2020 Nov;91(11):1210-8.Texto completo Resumo
186. Christine CW, Richardson RM, Van Laar AD, et al. Safety of AADC gene therapy for moderately advanced Parkinson disease: three-year outcomes from the PD-1101 Trial. Neurology. 2022 Jan 4;98(1):e40-50.Texto completo Resumo
187. Jankovic J, Goodman I, Safirstein B, et al. Safety and tolerability of multiple ascending doses of PRX002/RG7935, an anti-alpha-synuclein monoclonal antibody, in patients with Parkinson disease: a randomized clinical trial. JAMA Neurol. 2018 Oct 1;75(10):1206-14.Texto completo Resumo
188. Pagano G, Boess FG, Taylor KI, et al; PASADENA Investigators; Prasinezumab Study Group. A phase II study to evaluate the safety and efficacy of prasinezumab in early Parkinson's disease (PASADENA): rationale, design, and baseline data. Front Neurol. 2021 Oct 1;12:705407.Texto completo Resumo
189. Lang AE, Siderowf AD, Macklin EA, et al; SPARK Investigators. Trial of cinpanemab in early Parkinson's disease. N Engl J Med. 2022 Aug 4;387(5):408-20. Resumo
190. Pagano G, Taylor KI, Anzures-Cabrera J, et al; PASADENA Investigators; Prasinezumab Study Group. Trial of prasinezumab in early-stage Parkinson's disease. N Engl J Med. 2022 Aug 4;387(5):421-32. Resumo
191. Tison F, Keywood C, Wakefield M, et al. A phase 2A trial of the novel mGluR5-negative allosteric modulator dipraglurant for levodopa-induced dyskinesia in Parkinson's disease. Mov Disord. 2016 Sep;31(9):1373-80. Resumo
192. Addex Therapeutics. Dipraglurant-IR for PD-LID. 2022 [internet publication].Texto completo
193. ClinicalTrials.gov. PROSEEK: a phase 2 study in early Parkinson's disease patients evaluating the safety and efficacy of abl tyrosine kinase inhibition using K0706. NCT03655236. Nov 2022 [internet publication].Texto completo
194. ClinicalTrials.gov. Study in Parkinson disease of exercise (SPARX3). NCT04284436. Oct 2022 [internet publication].Texto completo
195. Hely MA, Reid WG, Adena MA, et al. The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years. Mov Disord. 2008 Apr 30;23(6):837-44.Texto completo Resumo
196. Jankovic J, Kapadia AS. Functional decline in Parkinson disease. Arch Neurol. 2001 Oct;58(10):1611-5.Texto completo Resumo
197. Marras C, McDermott MP, Marek K, et al. Predictors of time to requiring dopaminergic treatment in 2 Parkinson's disease cohorts. Mov Disord. 2011 Mar;26(4):608-13. Resumo
198. Velseboer DC, Broeders M, Post B, et al. Prognostic factors of motor impairment, disability, and quality of life in newly diagnosed PD. Neurology. 2013 Feb 12;80(7):627-33. Resumo
199. Kelberman MA, Vazey EM. New pharmacological approaches to treating non-motor symptoms of Parkinson's disease. Curr Pharmacol Rep. 2016 Dec;2(6):253-61.Texto completo Resumo
200. Severiano E Sousa C, Alarcão J, Pavão Martins I, et al. Frequency of dementia in Parkinson's disease: a systematic review and meta-analysis. J Neurol Sci. 2022 Jan 15;432:120077. Resumo
201. Wilby KJ, Johnson EG, Johnson HE, et al. Evidence-based review of pharmacotherapy used for Parkinson's disease psychosis. Ann Pharmacother. 2017 Aug;51(8):682-95. Resumo
202. Eng ML, Welty TE. Management of hallucinations and psychosis in Parkinson's disease. Am J Geriatr Pharmacother. 2010 Aug;8(4):316-30. Resumo
203. Iketani R, Furushima D, Imai S, et al. Efficacy and safety of atypical antipsychotics for psychosis in Parkinson's disease: a systematic review and Bayesian network meta-analysis. Parkinsonism Relat Disord. 2020 Sep;78:82-90. Resumo
204. Cummings J, Isaacson S, Mills R, et al. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial. Lancet. 2014 Feb 8;383(9916):533-40. Resumo
205. Espay AJ, Guskey MT, Norton JC, et al. Pimavanserin for Parkinson's Disease psychosis: effects stratified by baseline cognition and use of cognitive-enhancing medications. Mov Disord. 2018 Nov;33(11):1769-76.Texto completo Resumo
206. Liu B, Luo W, Mo Y, et al. Meta-analysis of related factors of impulse control disorders in patients with Parkinson's disease. Neurosci Lett. 2019 Aug 10;707:134313. Resumo
207. Weintraub D, Koester J, Potenza MN, et al. Impulse control disorders in Parkinson disease: a cross-sectional study of 3090 patients. Arch Neurol. 2010 May;67(5):589-95.Texto completo Resumo
208. Corvol JC, Artaud F, Cormier-Dequaire F, et al; DIGPD Study Group. Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology. 2018 Jul 17;91(3):e189-201.Texto completo Resumo
209. Stocchi F, Torti M. Constipation in Parkinson's disease. Int Rev Neurobiol. 2017 Jul 13;134:811-26. Resumo
210. Sakakibara R, Kishi M, Ogawa E, et al. Bladder, bowel, and sexual dysfunction in Parkinson's disease. Parkinsons Dis. 2011 Sep 12;2011:924605.Texto completo Resumo
211. Sakakibara R, Panicker J, Finazzi-Agro E, et al. A guideline for the management of bladder dysfunction in Parkinson's disease and other gait disorders. Neurourol Urodyn. 2016 Jun;35(5):551-63. Resumo
212. Hajebrahimi S, Chapple CR, Pashazadeh F, et al. Management of neurogenic bladder in patients with Parkinson's disease: a systematic review. Neurourol Urodyn. 2019 Jan;38(1):31-62. Resumo
213. Hauser RA, Heritier S, Rowse GJ, et al. Droxidopa and reduced falls in a trial of Parkinson disease patients with neurogenic orthostatic hypotension. Clin Neuropharmacol. 2016 Sep-Oct;39(5):220-6.Texto completo Resumo
214. Shibao C, Lipsitz LA, Biaggioni I, et al. Evaluation and treatment of orthostatic hypotension. J Am Soc Hypertens. 2013 Jul-Aug;7(4):317-24. Resumo
215. Isaacson SH, Skettini J. Neurogenic orthostatic hypotension in Parkinson's disease: evaluation, management, and emerging role of droxidopa. Vasc Health Risk Manag. 2014 Apr 3;10:169-76.Texto completo Resumo
216. Wallace DM, Wohlgemuth WK, Trotti LM, et al. Practical evaluation and management of insomnia in Parkinson's disease: a review. Mov Disord Clin Pract. 2020 Apr;7(3):250-66.Texto completo Resumo
217. Maski K, Trotti LM, Kotagal S, et al. Treatment of central disorders of hypersomnolence: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2021 Sep 1;17(9):1881-93.Texto completo Resumo
218. Howell M, Avidan AY, Foldvary-Schaefer N, et al. Management of REM sleep behavior disorder: an American Academy of Sleep Medicine clinical practice guideline. J Clin Sleep Med. 2023 Apr 1;19(4):759-68.Texto completo Resumo
O uso deste conteúdo está sujeito ao nosso aviso legal